Immunovant (IMVT) Current Leases (2020 - 2026)
Immunovant filings provide 6 years of Current Leases readings, the most recent being $98000.0 for Q1 2025.
- Quarterly Current Leases fell 28.99% to $98000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $98000.0 through Mar 2025, down 28.99% year-over-year, with the annual reading at $98000.0 for FY2025, 28.99% down from the prior year.
- Current Leases hit $98000.0 in Q1 2025 for Immunovant, up from $23000.0 in the prior quarter.
- Across five years, Current Leases topped out at $1.2 million in Q4 2022 and bottomed at $23000.0 in Q4 2024.
- Average Current Leases over 5 years is $736000.0, with a median of $1.1 million recorded in 2021.
- The largest annual shift saw Current Leases grew 11.68% in 2022 before it crashed 92.49% in 2024.
- Immunovant's Current Leases stood at $1.1 million in 2021, then increased by 11.68% to $1.2 million in 2022, then tumbled by 74.61% to $306000.0 in 2023, then tumbled by 92.48% to $23000.0 in 2024, then skyrocketed by 326.09% to $98000.0 in 2025.
- Per Business Quant, the three most recent readings for IMVT's Current Leases are $98000.0 (Q1 2025), $23000.0 (Q4 2024), and $47000.0 (Q3 2024).